Table 1.

The models of predicting the prognosis of rHCC.

	Model	Author	Sample/Method	Risk factor		Outcome
TAE for rHCC	Prediction of prognosis of TAE treatment of rHCC by imaging and clinical scoring systems	Ngan H et al	33/Mantel-Cox test	Total bilirubin=2.9 mg/dl		mOS 1 week
				Total bilirubin<2.9 mg/dl		mOS 15 weeks
		Okazaki M et al	38/Mantel-Cox test	Total bilirubin=3.0 mg/dl		mOS 13 days
				Total bilirubin ≤3.0 mg/dl		mOS 165 days
		Lee KH et al	111/Multiple logistic regression model	Bilobar tumor distribution(3points)	High risk≥4points	30 days mortality 86.8%
				Total bilirubin=2.5mg/dL(2points)	Moderate risk=3points	30 days mortality 31.8%
				Albumin <30g/L(1points)	Low risk ≤ 2points	30 days mortality 2.6%
		Fan WZ et al	94/Cox regression analysis	Shock index	≥0.6=<1	mOS 12.0 ± 1.0 days
					≥1	mOS 52.0 ± 7.2 days
				Child-Pugh score	10/11	mOS 51.0 ± 13.9 days
					12/13	mOS 28.0 ± 3.7 days
				Portal vein tumor thrombus	Main	mOS 14.0 ± 2.0 days
					Lobar	mOS 34.0 ± 5.1 days
					Segmental	mOS 52.0 ± 6.9 days
	MELD predicts TAE for rHCC	Jundt MC et al	24/Log-rank test	MELD-Na score=16		mOS 9 days, 30 days mortality 67%
				MELD-Na score ≤ 16		mOS 166.5 days, 30 days mortality 21%
Partial liver resection for rHCC	TAA	Wu JJ et al	139/Log-rank test	Scores according to the tumor size	High risk 10-13 points	1 year OS 30.2%
				Scores according to the AFP	Moderate risk 6-9 points	1 year OS 43.2%
				Scores according to the ALP	Low risk 0-5 points	1 year OS 88.1%
	AFP	Chua DW et al	79/Cox regression analysis	AFP=200 ng/mL		1 year OS 33.3%
				Tumor size=10 cm		1year recurrent rate 90.9%
		She WH et al.	114/Log-rank test	AFP≥256 ng/mL		mDFS 5.9 months
				AFP<256 ng/ml		mDFS 10.7 months

TAE, transcatheter artery embolization; rHCC, ruptured hepatocellular carcinoma; MELD, Model for End-Stage Liver Disease; mOS, median overall survival; TAA, tumor-associated antigen; AFP, alpha-fetoprotein; mDFS, median disease-free survival.